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Abstract 
Serology testing for COVID-19 is important in evaluating active immune response against SARS-
CoV-2, studying the antibody kinetics, and monitoring reinfections with genetic variants and new 
virus strains, in particular, the duration of antibodies in virus-exposed individuals and vaccine-
mediated immunity. In this work, recombinant S protein of SARS-CoV-2 was expressed in 
Rachiplusia nu, an important agronomic plague. One gram of insect larvae produces an amount of 
S protein sufficient for 150 determinations in the ELISA method herein developed. We 
established a rapid production process for SARS-CoV-2 S protein that showed immunoreactivity 
for anti-SARS-CoV-2 antibodies and was used as a single antigen for developing the ELISA 
method with high sensitivity (96.2%) and specificity (98.8%). Our findings provide an efficient 
and cost-effective platform for large-scale S protein production, and the scale-up is linear, thus 
avoiding the use of complex equipment like bioreactors.  
Graphical Abstract  
 












A rapid and cost-effective process for scale-up the production of SARS-CoV-2 Spike protein was 
developed in this work. The authors obtained high quality protein (trimeric and glycosylated 
state) after one step of purification from R. nu larvae. Our results demonstrate that the Spike 
protein produced in insect larvae is immunoreactive against the sera from COVID-19 patients and 
can be used as single antigen in immunoassays for the detection of anti-SARS-Cov-2 antibodies  
Keywords: SARS-CoV-2 coronavirus, insect larvae, trimeric spike, antibodies, ELISA 
Introduction 
The outbreak of a new virus, SARS-CoV-2, in December 2019 has had a serious impact on 
human health (Zhu et al., 2020). The severe acute respiratory syndrome related to this virus, 
officially designated COVID-19, has rapidly spread all over the world, progressing into a 
pandemic. This situation has urgently impelled many companies and public research institutes to 
concentrate their efforts on the search for effective vaccines, therapeutics, and diagnostic tests.  
 











SARS-CoV-2 is a single-stranded RNA-enveloped virus. The coronavirus spike (S) glycoprotein 
is surface-exposed in a large number of copies, and it mediates entry into host cells by interacting 
with angiotensin-converting enzyme 2 (ACE2) (Ke et al., 2020). For these reasons, S protein 
rapidly became the main target of neutralizing antibodies and the focus of therapeutic and vaccine 
design (Salvatori et al., 2020). In virions, the S protein exists as a large (over 500 kDa), highly 
glycosylated homotrimer, each monomer consisting of a globular head, the S1 subunit with its 
receptor-binding domain (RBD), and the S2 subunit, containing the protein-machinery that 
mediates viral-cell membrane fusion. The S protein normally exists in a metastable, prefusion 
conformation, but once the virus interacts with the host cell, an extensive rearrangement occurs, 
allowing the virus to fuse with the host cell membrane. The spikes are coated with polysaccharide 
molecules to camouflage themselves, evading surveillance by the host immune system during 
entry (Watanabe et al., 2020). 
Studies conducted in COVID 19 patients have reported that S and nucleocapsid (NCP) proteins 
are the main SARS-CoV-2 antibody targets (Burbelo et al., 2020). These antibodies are detectable 
from approximately 6 days after PCR confirmation of infection. It was demonstrated that those 
antibodies directed against RBD into S show a neutralizing capacity and, hence, can prevent 
infection (Seydoux et al., 2020; Suthar et al., 2020).  
Serological tests for COVID-19 are based on the detection of multiple targets of the virus, 
including S, RBD, NCP, and non-structural proteins, and are extensively used to identify whether 
people have been exposed to SARS-CoV-2 by looking at their immune response (Ghaffari et al., 
2020). During the pandemic, many efforts have been directed towards detecting, tracking, and 
better understanding human humoral responses to SARS-CoV-2 infection. It is crucial to develop 
robust and reliable serological assays to study the antibody kinetics and neutralization efficiency 
and monitor reinfections with genetic variants and new virus strains, in particular, the duration of 
antibodies in virus-exposed individuals and vaccine-mediated immunity. Currently, the RBD and 
 











S proteins are the most reliable antigens for measuring the abundance of neutralizing antibodies 
(Galipeau et al., 2020). 
Different strategies were described to obtain the S protein by biotechnological methods. Because 
of the structural complexity and post-translational modifications of the S protein, major efforts 
were directed to mammalian cell culture as a suitable productive system (Stuible et al., 2021). As 
already described, the S protein is a large homotrimer with 22 N‐linked glycosylation sites per 
monomer (Watanabe et al., 2020). As a consequence of its structural complexity, it is not 
surprising systems like Chinese hamster ovary (CHO) and human embryonic kidney (HEK) 
render low yields in mammalian (Esposito et al., 2020; Walls et al., 2020). Moreover, the great 
volume of culture media needed for S expression in mammalian cultures at a high scale is too 
expensive, especially to obtain this antigen for serological assays.  
We previously exhaustively studied the use of insect larvae such as Rachiplusia nu, an important 
agronomic plague in America, as a platform to produce different proteins in a short time and at a 
low cost (M. Targovnik et al., 2016). Also, we previously identified and described the 
chromatographic behavior of the main contaminant proteins present in the host to facilitate the 
downstream processing of any recombinant protein produced in this system (Mc Callum et al., 
2019). 
Here we established a rapid and cost-effective process for the expression and purification of a 
high-quality trimeric version of SARS-CoV-2 S protein by using the baculovirus-insect larvae 
system. This novel recombinant protein was used for developing a new serological ELISA test for 
COVID-19, showing high sensitivity and specificity with low operational complexity and cost. 
Materials and methods 
Recombinant virus construction 
 











We based our studies on a previously described version of SARS-CoV-2 S protein sequence, 
stabilized in its prefusion conformation (Wrapp et al., 2020). Briefly, the expressed protein was 
expected to include the ectodomain (residues 19-1207) of the SARS-CoV-2 Wuhan-Hu-1 S 
protein (GenBank: QHD43416.1) without native signal peptide, where the furin cleavage site 
(residues 682–685, PRRA) was removed (GSAS mutations) and residues at positions 986 (K) and 
987(V) were mutated to proline; additionally, a C-terminal T4 fibritin trimerization domain, a 
TEV protease cleavage site, and a histidine tag were included (Figure 1). For secretion, S protein 
was expressed under gp64 baculoviral signal peptide. The DNA sequence was codon-optimized 
for baculovirus expression and chemically synthesized (Genscript, Piscataway, NJ, USA). The S 
sequence and the enhanced green fluorescent protein (EGFP) cDNA were cloned into the 
pFastBacDual vector (Thermo Fisher Scientific, Waltham, USA) under the polyhedrin (polh) and 
p10 promoter, respectively, for expression in the baculovirus system. For this purpose, the EGFP 
(GenBank Accession No. NC_013179.1) was cloned into SmaI and Nco1 sites of the 
pFastBacDual vector (Targovnik et al., 2019)]. Then, the S cassette was subcloned into the 
pFastBacDual Vector into BamH1 and HindIII sites to generate the pFBD-p10-EGFP-polh-S 
construction. 
The recombinant baculoviruses were obtained using the Bac to Bac® baculovirus expression 
system (Thermo Fisher Scientific, USA), following the manufacturer’s instructions. The pFBD-
p10-EGFP-polh-S vector was transformed into a chemically competent E. coli DH10Bac™ strain 
(Thermo Fisher Scientific, USA) by heat shock to generate the recombinant bacmid by 
transposition. Then, the bacmids were purified and used to transfect 1 million Sf9 cells using 
Cellfectin II Reagent (Thermo Fisher Scientific, USA). After 4-day incubation at 27 °C, the cell 
culture supernatant was collected and centrifuged at 500 ×g for 10 min. The transfection 
efficiency was determined by measuring EGFP expression by fluorescence under UV light. The 
recombinant Autographa californica nuclear polyhedrosis virus (AcMNPV) polyhedrin-minus 
 











virus containing EGFP under the control of the p10 promoter and the S sequence under the 
control of the polyhedrin promoter was named rAcMNPV-S. Then, a round of amplification was 
performed in Sf9 cells seeded in T-25 flasks at 27 °C, at a low multiplicity of infection (MOI) of 
0.02. The Sf900 II insect cell culture medium and the antibiotic and antimycotic solutions were 
from InvitrogenTM (Gaithersburg, MD, USA) and the fetal bovine serum (FBS) was from 
Nutrientes Naturales S.A. (Buenos Aires, Argentina). The amplified rAcMNPV–S was titrated by 
plaque assay (O´Reilly DR, Miller LK, 1994). This high-titer rAcMNPV–S was the viral stock 
used for protein production in insect larvae. 
Expression of S protein in insect larvae 
R. nu larvae were from AgIdea (Pergamino, Argentina). They were reared in trays at 23–25 °C in 
a 70% humidified chamber, with a 16:8 light:dark photoperiod, and fed a high wheat-germ diet 
until they reached their fifth instar (20 days of age) prepared by AgIdea (Pergamino, Argentina). 
For all the experiments, batches of 500 fifth-instar larvae were injected with 50 µL of the 
recombinant baculovirus stock (diluted to 1×107 PFU mL−1) near the third prolegs, as shown in 
Figure 2. To characterize and quantify the recombinant protein produced, larvae that were alive 
and fluorescent under UV light were harvested at day 4 post-infection and frozen immediately 
at −80 °C until they were processed for analysis. Larvae infected with a non-related recombinant 
baculovirus were included as the control. 
Recombinant S protein purification by Immobilized Metal-Ion Affinity Chromatography (IMAC) 
In a typical process, 75 g of infected larvae were homogenized directly with 200 ml of 
equilibration buffer containing 10 mg glutathione crystals, 50 mM arginine, and 4 mM PMSF and 
1/200 (V/V) protease inhibitor cocktail (Sigma-Aldrich, Saint Louis, MO, USA) using a Bag Mixer 
400 homogenizer (Interscience, Saint-Nom-la-Bretèche, France). Then, the larval extract was 
 











centrifuged at 10,000×g for 30 min at 4 °C and the pellet was discarded. The supernatant was 
filtered through Whatman paper using a filter holder with a receptor (Nalgene, USA) to remove 
the lipid fraction remaining at the top. The filtered sample was centrifuged for a second time in 
the same conditions, and the supernatant was filtered through 3 µm (Sartopore o SartoBran 
capsules). Then, two experiments were conducted. In the first experiment, the clarified 
homogenate was loaded into the HisTrap FF 5 ml column (Cytiva, Marlborough, USA) previously 
equilibrated with 10CV (column volume) of 20 mM phosphate buffer, pH 7.4, 20 mM imidazole, 
300 mM NaCl, and 50 mM arginine, and washed with 10CV of the same buffer. The recombinant 
protein was eluted with a buffer containing 500 mM imidazole, 100 mM arginine, and 10% 
glycerol. In the second experiment, the same chromatography was done but the matrix was 
equilibrated with the same buffer containing 20 mM imidazole, a second wash was done with 80 
mM imidazole, and then the S protein was eluted with 500 mM imidazole. After that, an 
optimized protocol consisted in equilibrating the chromatographic matrix directly with the same 
buffer containing 80 mM imidazole, and after washing, the S protein was eluted by adding 500 
mM imidazole. In all cases, the linear flow rate was 0.4 cm min-1, and all fractions were 
collected and subjected to SDS-PAGE and Western blot analysis. 
Determination of protein concentration 
Total protein concentration was determined by the Bradford microassay protocol (Bradford, 
1976) using the Quick Start™ Bradford reagent (BioRad, Hercules, CA, USA). The samples used 
were crude larval extract and the purified S fraction. Additionally, the concentration of purified S 
protein was determined in an SDS-PAGE image with a diluted series of control bovine serum 
albumin. 
SDS-PAGE and Western Blot analysis 
 











Larval extracts and purification fractions were resolved by SDS-PAGE (10% polyacrylamide gels). 
Before loading the samples into the wells, they were heated for 5 min at 100 °C in sample buffer 
(125 mM Tris–HCl, pH 6.8, 4% [w/v] SDS, 20% [w/v] glycerol, 0.01% [w/v] bromophenol blue, 
and 10% [v/v] 2-mercaptoethanol). One of the lanes was reserved for the protein marker to 
determine the MW of the protein bands. The resulting gels were either stained with Coomassie 
Blue R-250 or transferred onto nitrocellulose membranes (Cytiva, Marlborough, USA). 
Membranes were then incubated overnight at 4 °C in blocking solution (phosphate-buffered 
saline [PBS]—3% skim milk [PBS-M]). After a 10-min wash with PBS containing 0.05% v/v Tween 
20 (PBS-T), the membrane was incubated for 2 h with mouse anti-His antibody (BD Biosciences, 
USA) 1/2,500 in 0.05% PBS-T-1% skim milk, and then washed three times with PBS-T. Polyclonal 
rabbit anti-mouse immunoglobulin conjugated with HRP (1/30,000 in 0.05% PBS-T-1% skim milk) 
was used as the secondary antibody. Development was carried out with 3,3'-diaminobenzidine 
(DAB) (Sigma-Aldrich, USA) staining or, alternatively, with an enhanced chemiluminescent 
substrate (ECL) and high-performance chemiluminescence films (CL-X Posure™, Thermo Fisher 
Scientific, USA).  
Characterization of the recombinant S protein expressed in R. nu 
Size exclusion chromatography 
The oligomerization state of the recombinant S protein was evaluated by high-resolution size 
exclusion chromatography (SEC). Elution fractions from IMAC containing purified S protein 
were collected and concentrated, and the buffer was exchanged and loaded on a Superdex 200 
increase 10/300 (Cytiva, Marlborough, USA) equilibrated in 100 mM sodium phosphate buffer, 
150 mM NaCl, pH 7.4. All fractions were collected, and the S protein was revealed by WB using 
an anti-6x His-tag antibody, as described previously. The calculated molecular weight (MW) of 
the expressed protein, without considering the glycan moieties, was 138914 Da. 
 












Healthy control individuals 
Control serum/plasma (n = 83) was obtained from samples collected from healthy individuals 
before the outbreak of SARS-CoV-2. The sample collection was approved by the Ethics 
Committee of José de San Martín Clinical Hospital, University of Buenos Aires (UBA), Buenos 
Aires, Argentina. Sera were stored at -20°C until assayed. 
COVID-19 patients 
Serum/plasma samples were collected from a total of 98 COVID-19 cases confirmed to be 
infected with SARS-CoV-2 by real-time RT-PCR (rRT-PCR) on samples from the respiratory 
tract. These samples were provided by the Biobank of Infectious Diseases (BBEI) of the Institute 
for Biomedical Research on Retroviruses and AIDS (INBIRS). Seventy-eight of these samples 
were IgG positive and 20 were IgG negative for SARS-CoV-2 by COVIDAR IgG ELISA test 
(Laboratorio Lemos S.R.L., Argentina). Sample collection and protocols were approved by the 
Ethics Committee of BBEI-INBIRS and the Ethics Committee in Clinical Research of the School 
of Pharmacy and Biochemistry, UBA. All subjects were informed about the purpose of the study, 
and they signed consent for study participation. Sera were stored at -20°C until assayed. 
Spike application in an immunoassay for antibodies for SARS-CoV-2 assessment 
Reagents 
PBS was used as the microplate coating buffer. PBS-M and PBS-T were used as blocking 
solution and washing buffer, respectively. Sample or reagent dilutions were prepared in 3 % w/v 
skim milk, 0.05 % v/v Tween 20 in PBS (PBS-MT). Streptavidin–Horseradish Peroxidase (HRP) 
and rabbit anti-human IgG-biotin were purchased from Jackson ImmunoResearch Laboratories, 
Inc. (USA). The 3,3’,5,5’-tetramethyl-benzidine/ H2O2 (Single Component TMB Peroxidase EIA 
 











Substrate Kit, BioRad, Hercules, CA, USA) was employed as the chromogenic substrate. Except 
when otherwise indicated, incubations were performed at RT, washing steps were performed with 
PBS-T, and 50 μL per well were added in each incubation step. 
ELISA with colorimetric detection  
Polystyrene microplates (Maxisorp, NUNC, Roskilde, Denmark) were coated overnight at 4 °C 
with 0.1μg purified Spike per well, in coating buffer, and washed five times with PBS. Blocking 
solution (200 μL/well) was added, and plates were incubated for 1 h. After washing six times, 
duplicate serum samples diluted 1/100 (100 μL/well) were added and incubated for 1 h. 
Microplates were washed six times and incubated for 30 min at 37 oC with anti-human IgG-biotin 
(diluted 1/180,000). Plates were washed six times, and bound antibodies were detected with 
Streptavidin-HRP (diluted 1/2,000, 30 min at 37 °C). After washing (five times plus one final 
wash with PBS), the chromogenic substrate was added and plates were incubated for 15 min in 
the dark. The color reaction was stopped with 2 M H2SO4. The oxidized substrate was measured 
at 450 nm with an ELISA plate reader MultiskanFC (Thermo Scientific Labsystems, USA). The 
blank control was made by replacing serum samples with PBS-MT. Results were calculated as 
specific absorbance (A = the mean of each sample minus the mean of the blank control) and 
expressed as Standard Deviation scores: SDs = (A-Ac)/SDc, where Ac is the mean specific 
absorbance of healthy control sera and SDc its standard deviation. The cut-off value of the assay 
was set at SDs = 3.0. 
Statistical analysis 
The normal distribution of data was analyzed by the D’Agostino and Pearson omnibus normality 
test. To remove outliers from normally distributed healthy control individuals, the Rout test was 
performed. The selection of optimal cut-off values was based on curves constructed by plotting 
the calculated specificity and sensitivity vs. the corresponding cut-off values. Statistical 
 











significance was evaluated using either parametric tests: paired-samples Student t-test and 
unpaired-samples Student t-test with Welch correction, or non-parametric tests: Wilcoxon 
matched-pairs signed-rank test or Mann-Whitney U-test for unpaired data, when applicable. 
Calculations were performed using GraphPad Prism version 6.01 for Windows (GraphPad 
Software, San Diego California, USA, www.graphpad.com). A p-value < 0.05 was considered 
statistically significant. 
Result and Discussion 
Expression and purification of the recombinant spike in insect larvae 
A low-cost alternative to cell culture-based protein production is the use of live insect larvae as 
“mini bioreactors”. To obtain the recombinant version of the S protein, we cloned the expression 
cassette into the pFastBacDualGFP vector under the control of the strong baculovirus polyhedrin 
promoter. The expression cassette included gp64 signal peptide, which targets the recombinant 
protein to the secretion pathway. After transfection and amplification in Sf9 insect cells, a 
recombinant baculovirus seed-stock for expression in larvae was obtained. Insect larvae support 
many of the post-translational modifications that enable proteins to achieve their biologically 
functional native conformation (Loustau et al., 2008). 
R. nu larvae were infected by injection of the baculovirus by intrahemocele injection with 
approximately 5x105 pfu of viral stock (Figure 2a-b). From our experience, this dose was the best 
option to achieve a high level of S protein expression and no larval mortality. The larvae infected 
with the recombinant baculovirus expressed, in addition to the proteins of interest, the EGFP 
protein, which allowed us to determine the optimum day of harvest by observation under UV 
light. At 4 day post infection (dpi), the fluorescence was maximal, and then the viability of the 
larvae decreased significantly. Therefore, the larvae were harvested at 4 dpi under a UV lamp 
using fluorescence as an indicator of infection. We proceeded to obtain the clarified homogenate 
 











from the larvae and purify the recombinant proteins expressed in insect larvae R. nu by IMAC. 
The gp64 signal peptide was effective to target S protein to the secretory pathway. The 
recombinant S protein was secreted to hemolymph and this localization made it easier to extract it 
from the larvae.  
SDS-PAGE revealed that most of the proteins of the crude extract were removed in the 
passthrough fraction during purification by IMAC when the sample was loaded without 
imidazole. However, when the bound material, containing the protein of interest, was desorbed 
after a single 500 mM imidazole step, an important contaminant of hemolymph (hexamerin, 76 
kDa approx.) was still present in the elution fraction. After some rounds of optimization, we 
concluded that when the extracts were run directly on the chromatographic matrix previously 
equilibrated with 20 mM imidazole, most contaminants, including hexamerin, eluted in the 
passthrough or washing fractions, while the recombinant S protein remained bound to the matrix. 
Nevertheless, in this condition, another contaminant with a molecular weight similar to that of the 
S protein was present and eluted with 80 mM imidazole (Figure 3). For these reasons, we 
assessed a new protocol, which directly equilibrated the matrix with the same buffer containing 
80 mM imidazole. As judged by reducing SDS-PAGE and WB, the estimated molecular weight 
of the recombinant S protein was 150 kDa (monomer), indicating that it was correctly 
glycosylated and did not suffer protease degradation (Figure 3). Other authors have expressed the 
ectodomain of S protein with the native peptide sequence in hemolymph of Bombyx mori larvae 
and reported that recombinant protein was cleaved probably by a host furin-protease. In the same 
work, the authors resolved it with a version of S protein modified in furin protease-target site 
(Fujita et al., 2020). In the present work, we decided to synthesize a version of S protein where 
the furin cleavage site (residues 682–685, PRRA) was removed because furin protease activity 
was only described in Spodoptera frugiperda, a R. nu related species (Westenberg et al., 2002). 
 











The amount of recombinant S protein was 15 ug/g of larvae at 4 dpi on our platform based on R. 
nu. The process based on Bombyx mori previously reported by other authors (Fujita et al., 2020) 
can be compared with ours as follows: in both cases, the optimal day of S protein harvest was 4 
dpi after larval infection; however, in Bombyx mori, it was necessary to extract the whole 
hemolymph of each larva for purification while, in our case, a complete extract was done with all 
infected larvae, thus simplifying the biotechnological process. In B. mori, the estimated value of 
the purified S protein from 10 ml hemolymph (35 larvae) was 100 µg, and the same yield was 
obtained with 45 R. nu larvae in the process herein described.  
Protein quality assessment 
We assessed whether insect larvae-produced SARS CoV-2 S protein was suitable for our 
intended use. The trimetric nature of the S protein, which is typical of Type I viral fusion 
proteins, is a critical quality attribute of recombinant S proteins in different expression systems 
(Esposito et al., 2020). We evaluated the oligomeric state of the IMAC-purified S protein from R. 
nu larvae by size exclusion chromatography (SEC) in a Superdex 200 column. Figure 4a shows a 
typical SEC chromatogram of the larvae-expressed SARS CoV-2 S protein eluting as a broad 
peak with an elution volume close to 10 ml, compatible with a 450-500 kDa protein, in good 
accordance with the expected trimeric nature of the purified protein. The S monomer is a protein 
with an apparent molecular weight of ~ 150 kDa bearing many glycan moieties, which affects its 
hydrodynamic behavior (the MW calculated from the amino acid sequence is 138 kDa). The 
presence of S protein in these fractions was confirmed by WB, using an anti 6xHis tag-specific 
antibody (Figure 4b). Notably, two peaks, denoted as peak #1 and #2, were also observed. 
However, these peaks were not recognized by the anti 6xHis tag antibody in the WB revealed 
with ECL (Figure 4b), indicating that they might correspond to non-related impurities or to a 
dissociated and fragmented S protein with its carboxyl-terminal cleaved. It should be noted that 
 











some proteolysis can occur during concentration and buffer exchange of the sample performed 
before injecting on a SEC column. 
SPIKE application in an immunoassay for antibodies for SARS-CoV-2 assessment 
The immunochemical behavior of the recombinant version of the S protein expressed in insect 
larvae R. nu was evaluated during the following use as an immobilized antigen in the 
development of an indirect ELISA aimed at detecting the presence of anti-S specific IgG 
antibodies in human serum/plasma samples. After an initial round of optimization (antigen 
concentration and binding conditions, primary and secondary antibodies dilution, washing steps), 
a panel of 83 human control serum/plasma and 98 COVID-19 patients’ serum/plasma were 
analyzed. To calculate the coefficient variation, a positive serum from a COVID-19 patient was 
employed. The intra-assay coefficient variation was 3.21% (n = 2) and the inter-assay coefficient 
variation was 20.11% (n = 4). The test performance was optimized in terms of sensitivity and 
specificity by evaluating the effect of different cut-off values (in SDs) on receiver operating 
characteristic curves (ROC) (Figure 5). The area under the ROC curve (AUC) was 0.893, 
indicating that the method had high accuracy to distinguish between samples from the two groups 
under study (Carter et al., 2016). When a cut-off value of 3.0 SDs was established, 75 out of 78 
COVID-19 samples that tested positive by COVIDAR IgG ELISA Test, were also positive by our 
developed ELISA (sensitivity: 96.2%). The specificity, calculated as 100% minus the percentage 
of true negative samples (normal human sera, n = 83) detected as positive, was 98.8%. The 
median SDs range of true negative samples was -0.22 (range: -1.78 to 3.21) and the median SDs 
range of true positive samples was 7.32 (range: 0.00 to 23.20). Moreover, the concordance 
between the ELISA developed herein and the COVIDAR IgG ELISA test was 95.96%, with a 
kappa statistic of 0.879, representing a substantial agreement between the two methods. The 
results presented in the present work demonstrate that the Spike protein produced in insect larvae 
is immunoreactive against the sera from COVID-19 patients and can be used in immunoassays 
 











for the detection of anti-SARS-Cov-2 antibodies (Figure 6). The strategy reported herein should 
be accessible to many laboratories and should allow the easy production of Spike. In turn, the 
availability of properly folded Spike would encourage researchers to improve current and develop 
new immunochemical tests for anti-SARS-Cov-2 antibodies detection. 
On the other hand, it is known that cellular immune response to SARS-CoV-2 is critical in 
controlling disease. For this reason it is important to analyze the magnitude and phenotype of the 
SARS-CoV-2-specific T cell response. For this purpose different authors have employed peptide 
pools from a range of viral proteins, including spike, nucleoprotein and membrane protein (Zuo et 
al., 2021). Additionally, other authors have evaluated T-cells proliferation after stimulation with 
these proteins (Avendaño-Ortiz et al., 2020). In view of that, S protein produced in insect larvae 
could be also employed for this purpose. 
Conclusions 
In this work, we show that SARS-CoV-2 recombinant S protein could be produced inexpensively 
after infection of R. nu larvae and easily purified later after a single chromatographic step. 
Noteworthy, the antigenic properties of this large, complex, highly glycosylated protein are 
retained, as evidenced during its application for developing a serologic ELISA test. One gram of 
insect larvae produces an amount of S protein sufficient for 150 determinations in the ELISA 
method. The scale-up of S protein production is linear in this biotechnological platform, avoiding 
the use of complex equipment like bioreactors. Thus, it is straightforward to conclude that our 
approach represents a rapid, easy, and cost-effective method for the production of recombinant S 
for diagnostic applications. We expect that our approach will bring new tools for serologic test 
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Legends 
Figure 1. SARS-CoV-2 S protein including the ectodomain (residues 19-1207) without 
native signal peptide. The furin cleavage site was removed (GSAS mutations) and 
residues at positions 986 (K) and 987(V) were mutated to proline. The C-terminal 
included a 4 fibritin trimerization domain, a TEV protease cleavage site, and a histidine 
tag. 
Figure 2. Rachiplusia nu larvae. a. A batch of 500 fifth-instar larvae. b. Injection of the 
recombinant baculovirus near the third prolegs.  
Figure 3. Purification of S protein by IMAC. a. SDS-PAGE with Coomassie blue 
staining. b. Western blot with DAB staining. Lanes: MK. molecular weight marker. 1. 
Larval extract (input). 2. Passthrough. 3. Wash fraction with 80 mM imidazole. 4. Elution 
fraction with 500 mM imidazole. 
Figure 4. Size exclusion analysis of S protein purified by IMAC. a) Chromatogram 
showing the elution profile of S protein in IMAC. The void volume (Blue dextran) of the 
column is ~8.8 ml, and the monomeric (~67 kDa) and dimeric (~140 kDa) forms of 
Bovine Serum Albumin (BSA) eluting at ~12.5 ml and ~14.4 ml, respectively, are shown 
for reference with bars at the top of the chromatogram. The asterisk indicates the peak 
containing Spike trimer. Fractions subjected to WB staining with ECL (from 2 to 14) are 
indicated at the bottom of the chromatogram. 4b) WB of SEC eluted fractions. Protein 
was revealed using an anti 6xHis tag antibody and ECL. Lane M, molecular weight 
 











markers; lane C, positive control; lane 1, input; lanes 2 to 14 correspond to respective 
fractions obtained from the SEC column.  
Figure 5: Analysis of ELISA performance resulting from the study of 83 sera from 
normal control individuals and 98 sera from COVID-19 patients. (A) Sensitivity curve 
(o) and specificity (x) as a function of the possible cut-off values. The vertical dashed line 
indicates the cut-off value with the optimized sensitivity and specificity parameters (cut-
off = 3.0). (B) ROC curve analysis of ELISA, AUC is included. 
Figure 6: Antibodies anti-SARS-CoV-2 results obtained by ELISA in sera from normal 
control individuals and sera from COVID 19 patients IgG positive and negative by 
COVIDAR IgG ELISA test. Results are expressed as SDs. The cut-off value (SDs >3.0) 
is indicated by a dotted line and medians for each population are indicated as a full line 
(***p<0.0001). The values for the dots found on the cut-off line are as follow: Controls 
subjects (n=3): 2.81, 3.21 and 2.86; Patients COVIDAR IgG + (n=1): 2.81 and Patients 
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